Skip to content
AnalystLens

Halozyme Therapeutics Annual Report, Year Ended Dec 31, 2010

Filing Date
Filed March 11, 2011
Period End
December 31, 2010
Security
HALO
In the record · 2016–202610-K1110-Q338-K141

HALO filed 11 annual reports (10-K), 33 quarterly reports (10-Q) and 141 current reports (8-K) between 2016 and 2026.

  1. Leadership change8-K · Mar ’18Mar ’18
  2. FY2019 annual report10-K · Feb ’20Feb ’20
  3. Deal closed8-K · May ’22May ’22
  4. Leadership change8-K · Dec ’25Dec ’25

Summary

Summary of the 10-K filed March 11, 2011. Cited figures are marked; the original filing is the authoritative source.

Halozyme Therapeutics, Inc. reported total revenues of $13,624,115a for 2010, compared with $13,671,305 in 2009, while its net loss narrowed to $53,241,650 ($0.56 per share) from $58,360,523 ($0.67 per share).

Product sales were $895,518b and revenues under collaborative agreements were $12,728,597. Research and development expense was $51,773,504 and selling, general and administrative expense was $15,122,960. The company has never been profitable and reported an accumulated deficit of $225,251,795 at December 31, 2010.

The filing describes a year of significant setbacks and restructuring. HYLENEX was voluntarily recalled in May 2010 because a portion manufactured by Baxter did not comply with agreement requirements. In January 2011, Halozyme and Baxter agreed to terminate the HYLENEX Partnership, and Halozyme reacquired worldwide HYLENEX marketing rights.

The company says it expects to reintroduce HYLENEX in the second half of 2011, subject to FDA review. In October 2010, a reorganization cut the workforce by approximately 25 percent, and Jonathan E. Lim, M.D. resigned as CEO in December 2010, with Gregory I.

Frost, Ph.D. succeeding him. The company's pipeline centers on its rHuPH20 enzyme, with its lead proprietary program being an ultrafast insulin program and a PEGylated version, PEGPH20, in Phase 1 testing for solid tumors.

Partnered programs include Roche's subcutaneous Herceptin and MabThera, which are in Phase 3, and Baxter's GAMMAGARD LIQUID. Management states that cash and cash equivalents of $83,255,848c are sufficient to fund operations for at least the next twelve months, and it anticipates net cash burn of approximately $47.0 to $52.0 million for 2011.

Key Highlights

  1. Total revenues were $13,624,115 in 2010, roughly flat versus $13,671,305 in 2009; collaborative revenues were $12,728,597.
  2. Net loss narrowed to $53,241,650 ($0.56 per share) in 2010 from $58,360,523 ($0.67 per share) in 2009.
  3. Cash and cash equivalents were $83,255,848 at December 31, 2010; management expects this to fund operations for at least the next twelve months.
  4. Anticipated 2011 net cash burn is approximately $47.0 to $52.0 million.
  5. HYLENEX was recalled in May 2010; Baxter partnership terminated January 2011, returning worldwide HYLENEX marketing rights to Halozyme, with reintroduction targeted for the second half of 2011 pending FDA approval.
  6. Roche and Baxter partnerships continue, including Roche Phase 3 trials of subcutaneous Herceptin and MabThera; Roche expects to file for approval of subcutaneous Herceptin in 2012.
  7. Net proceeds of approximately $60.0 million from a September 2010 common stock offering at $7.25 per share, and a 25 percent workforce reduction in October 2010.

Financial Statements

FY2010 against FY2009

Line itemFY2010FY2009Change
Revenue$13.62M$13.67M−0.3%
Cost of Revenue$985K$312K+215.9%
Gross Profit$12.64M$13.36M−5.4%
R&D Expenses$51.77M$56.61M−8.6%
SG&A Expenses$15.12M$15.20M−0.5%
Operating Expenses$67.88M$72.13M−5.9%
Operating Income-$54.26M-$58.46M+7.2%
Net Income-$53.24M-$58.36M+8.8%
EPS (Basic)$-0.56$-0.67+16.4%

Frequently Asked Questions

  1. Is Halozyme close to profitability?

    No. The company states it has never been profitable, has incurred net losses each year since inception, and had an accumulated deficit of $225,251,795 at December 31, 2010. It expects significant operating losses over the next few years.

  2. Will the company need more capital soon?

    The company believes current cash of $83,255,848 is sufficient for at least the next twelve months, but it says it may wish to raise additional capital and that future financing may not be available on favorable terms. It also notes that its cash position may not be sufficient to fund development of its proprietary candidates for several years.

  3. What happened to HYLENEX and when could it return?

    HYLENEX was voluntarily recalled in May 2010 because a portion manufactured by Baxter did not meet agreement requirements. Halozyme and Baxter terminated the HYLENEX Partnership effective January 7, 2011, and the company expects to reintroduce the product in the second half of 2011, pending regulatory review and approval. The filing notes this timeline is not assured.

  4. What are the company's main growth drivers?

    The filing points to its ultrafast insulin program, which combines rHuPH20 with mealtime insulins and includes Phase 2 trials completed or fully enrolled, and to PEGPH20, a PEGylated enzyme in Phase 1 trials for solid tumors. Partnered products include Roche's subcutaneous Herceptin and MabThera, both in Phase 3, and Baxter's GAMMAGARD LIQUID, for which Baxter expects to file for approval in 2011.

  5. What are the key risks to the investment?

    Key risks include reliance on contract manufacturers Avid and Cook for API supply, dependence on partners for regulatory and commercial success, possible FDA delays or rejection of product candidates, the uncertain timing of HYLENEX's return, intellectual property challenges (including an opposition to the European patent EP1603541), and stock price volatility. Management also notes that its stock trades at historically low volume.